Amgen Inc. $AMGN Holdings Trimmed by Access Financial Services Inc.

Access Financial Services Inc. reduced its position in shares of Amgen Inc. (NASDAQ:AMGN) by 46.8% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 2,066 shares of the medical research company’s stock after selling 1,820 shares during the period. Access Financial Services Inc.’s holdings in Amgen were worth $676,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMGN. Capital Management Associates Inc acquired a new stake in shares of Amgen during the 4th quarter valued at $277,000. Buffalo Business & Estate Services Ltd. acquired a new position in shares of Amgen in the 4th quarter worth $5,471,000. Sunburst Financial Group LLC grew its holdings in shares of Amgen by 2.6% in the 4th quarter. Sunburst Financial Group LLC now owns 1,602 shares of the medical research company’s stock worth $524,000 after acquiring an additional 40 shares during the last quarter. Leo Wealth LLC raised its position in shares of Amgen by 107.6% during the fourth quarter. Leo Wealth LLC now owns 1,827 shares of the medical research company’s stock worth $598,000 after purchasing an additional 947 shares during the period. Finally, Walkner Condon Financial Advisors LLC raised its position in shares of Amgen by 6.4% during the fourth quarter. Walkner Condon Financial Advisors LLC now owns 964 shares of the medical research company’s stock worth $316,000 after purchasing an additional 58 shares during the period. 76.50% of the stock is currently owned by institutional investors.

Amgen Stock Performance

NASDAQ:AMGN opened at $347.94 on Monday. The company has a market capitalization of $187.56 billion, a P/E ratio of 24.45, a P/E/G ratio of 3.45 and a beta of 0.47. The stock’s 50 day moving average price is $363.65 and its 200 day moving average price is $333.18. The company has a debt-to-equity ratio of 5.78, a quick ratio of 0.90 and a current ratio of 1.14. Amgen Inc. has a 52 week low of $261.43 and a 52 week high of $391.29.

Amgen (NASDAQ:AMGN) last posted its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.76 by $0.53. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The firm had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. During the same period in the previous year, the company earned $5.31 earnings per share. The company’s revenue was up 8.6% compared to the same quarter last year. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. On average, research analysts forecast that Amgen Inc. will post 20.62 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be paid a $2.52 dividend. This represents a $10.08 annualized dividend and a dividend yield of 2.9%. The ex-dividend date of this dividend is Friday, May 15th. Amgen’s payout ratio is presently 70.84%.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Royal Bank Of Canada increased their price target on Amgen from $335.00 to $360.00 and gave the company an “outperform” rating in a research report on Wednesday, February 4th. HSBC reissued a “buy” rating and issued a $425.00 price target on shares of Amgen in a research note on Wednesday, December 10th. Daiwa Securities Group upped their price objective on shares of Amgen from $370.00 to $410.00 and gave the company an “outperform” rating in a research note on Tuesday, February 10th. Sanford C. Bernstein cut shares of Amgen from an “outperform” rating to a “market perform” rating and set a $335.00 target price for the company. in a report on Tuesday, January 20th. Finally, Leerink Partners restated a “market perform” rating and set a $355.00 price target on shares of Amgen in a report on Thursday, March 5th. One investment analyst has rated the stock with a Strong Buy rating, fourteen have given a Buy rating, thirteen have assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat, Amgen presently has a consensus rating of “Hold” and an average price target of $354.60.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.